Drug shown to reverse radioiodine resistance in some advanced thyroid cancers
Memorial Sloan-Kettering will lead phase III trial of investigational drug
18-Feb-2013 -
The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center.
Published in the issue of the New England Journal ...
AstraZeneca
cancer
genetic mutations
+4